Number of the records: 1  

Small change – big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity

  1. 1.
    SYSNO ASEP0575940
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleSmall change – big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity
    Author(s) Voňka, Petr (UEB-Q) ORCID
    Rárová, L. (CZ)
    Bazgier, V. (CZ)
    Tichý, V. (CZ)
    Kolářová, T. (CZ)
    Holčáková, J. (CZ)
    Berka, K. (CZ)
    Kvasnica, Miroslav (UEB-Q) RID, ORCID
    Oklešťková, Jana (UEB-Q) RID, ORCID, SAI
    Kudová, Eva (UOCHB-X) RID, ORCID
    Strnad, Miroslav (UEB-Q) RID, ORCID
    Hrstka, Roman (UEB-Q) ORCID
    Number of authors12
    Article number106365
    Source TitleJournal of Steroid Biochemistry and Molecular Biology. - : Elsevier - ISSN 0960-0760
    Roč. 233, OCT (2023)
    Number of pages13 s.
    Languageeng - English
    CountryGB - United Kingdom
    KeywordsApoptosis ; Docking of steroid library ; Estrogen receptor alpha ; Luciferase assay ; Mitochondrial membrane potential
    OECD categoryBiochemistry and molecular biology
    R&D ProjectsLM2023055 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    LX22NPO5102 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    Research Infrastructuree-INFRA CZ - 90140 - CESNET, zájmové sdružení právnických osob
    BBMRI.cz IV - 90233 - Masarykův onkologický ústav
    Method of publishingOpen access
    Institutional supportUEB-Q - RVO:61389030 ; UOCHB-X - RVO:61388963
    UT WOS001048999000001
    EID SCOPUS85165571434
    DOI10.1016/j.jsbmb.2023.106365
    AnnotationEstrogen receptor alpha (ER) is a key biomarker for breast cancer, and the presence or absence of ER in breast and other hormone-dependent cancers decides treatment regimens and patient prognosis. ER is activated after ligand binding typically by steroid. 2682 steroid compounds were used in a molecular docking study to identify novel ligands for ER and to predict compounds that may show anticancer activity. The effect of the most promising compounds was determined by a novel luciferase reporter assay. Two compounds, 7 and 12, showing ER inhibitory activity comparable to clinical inhibitors such as tamoxifen or fulvestrant were selected. We propose that the inhibitory effect of compounds 7 and 12 on ER is related to the presence of a double bond in their D-ring, which may protect against ER activation by reducing the electron density of the keto group, or may undergo metabolism leading to an active compound. Western blotting revealed that compound 12 decreased the level of ER in the breast cancer cell line MCF7, which was associated with reduced expression of both isoforms of the progesterone receptor, a well-known downstream target of ER. However, compound 12 has a different mechanism of action from fulvestrant. Furthermore, we found that compound 12 interferes with mitochondrial functions, probably by disrupting the electron transport chain, leading to induction of the intrinsic apoptotic pathway even in ER-negative breast cancer cells. In conclusion, the combination of computational and experimental methods shown here represents a rapid approach to determine the activity of compounds towards ER. Our data will not only contribute to research focused on the regulation of ER activity but may also be useful for the further development of novel steroid receptor-targeted drugs applicable in clinical practice.
    WorkplaceInstitute of Experimental Botany
    ContactDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Year of Publishing2024
    Electronic addresshttps://doi.org/10.1016/j.jsbmb.2023.106365
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.